What's New New Analyst Reports Information What's New 05/08/2024NEWCENTRAL SECURITY PATROLS(9740)NOTICE OF THE 52nd ANNUAL GENERAL MEETING OF SHAREHOLDERSTOHO(9602)Partial Correction to the Notice of the 135th Annual General Meeting of Shareholders05/07/2024NEWMELCO HOLDINGS(6676)[Delayed]Notice Concerning Recording of Extraordinary LossesMcdonald's Holdings(Japan)(2702)Monthly IR NewsEarth Corporation(4985)Notice on the Progress of the Acquisition of Own SharesFast Fitness Japan(7092)Fast Fitness Japan Obtains Master Franchisee Rights for Anytime Fitness in Germanycreate restaurants holdings(3387)Notice of the 27th Ordinary General Meeting of Shareholders05/02/2024HUB(3030)NOTICE OF THE 26th ANNUAL GENERAL MEETING OF SHAREHOLDERSALINCO(5933)Consolidated Financial Results for the Fiscal Year Ended March 20, 2024 (Under Japanese GAAP)TMS(4891)Notice of the 20th Annual General Meeting of Shareholders05/01/2024AEON DELIGHT(9787)Analyst Report(Shared Research) : Interview following the Announcement of Financial Results for FY02/24 [Report Update]Infomart(2492)Analyst Report(Shared Research) : Released Q1 FY12/24 resultsSegue Group(3968)[Delayed]Notice of Revision to Full-year Business Forecasts and Recording of Gain on Valuation of Derivatives04/30/2024Infomart(2492)Consolidated Financial Results for the Three Months Ended March 31, 2024 (Under Japanese GAAP)Carna Biosciences(4572)Analyst Report(Shared Research) : Interview following the Announcement of Financial Results for full-year FY12/23 [Report Update]04/27/2024AEON DELIGHT(9787)Notice of the 51th Annual General Meeting of Shareholders04/26/2024WATTS(2735)Consolidated Financial Results for the Six Months Ended February 29, 2024 (Under Japanese GAAP)Open Up Group(2154)Notice of Monthly Disclosure of Utilization Rates and March of Domestic Engineers and WorkSBI Leasing Services(5834)Consolidated Financial Results for the Fiscal Year Ended March 31, 2024 (Under Japanese GAAP)EPCO(2311)Analyst Report(Shared Research) : Monthly results for March 202404/25/2024ELECOM(6750)Notice Regarding conclusion of non-binding Memorandum of Understanding on Acquisition of Full Ownership of Nippon Antenna Co., Ltd. through a Share ECTI Engineering(9621)Notice of Disposal of Treasury Shares as Restricted Stock Compensation04/24/2024SEPTENI HOLDINGS(4293)Corporate Governance ReportNICHIREKI(5011)Notice Concerning Personnel Changes of Directors after Transition to a Company with an Audit and Supervisory Committee04/22/2024WATTS(2735)Operating Results for the Six Months of the Fiscal Year Ending August 2024 and Progress of the Full-Year PlanELECOM(6750)Notice regarding a Merger with a Consolidated SubsidiaryFerrotec Holdings(6890)Notice of the Issuance of New Shares Based on Restricted Stock Units (RSUs)Tokyo Individualized Educational Institute(4745)Earnings Briefing Materials for FY2023TOHO(9602)Notice of the 135th Annual General Meeting of Shareholders04/19/2024create restaurants holdings(3387)Notice of Dividend Payment from Retained Earnings (Year-end Dividend)Earth Corporation(4985)Notice Concerning Completion of Payment for Issuance of New Shares as Remuneration for Restricted StockCarna Biosciences(4572)Analyst Report(Shared Research) : ssuance of new shares under a restricted stock compensation scheme04/18/2024TOHO(9602)Notice Concerning Results of Acquisition of Own Shares Through Off-Auction Own Share Repurchase Trading System (ToSTNeT-3)Notice Concerning Dividends of Surplus04/17/2024AnGes(4563)Notice on the NHI Drug Price Standard Listing and Launch Schedule of Zokinvy for the Treatment of ProgeriaCTI Engineering(9621)[Delayed]Notice of Receipt of Investigation Report by Internal Investigation Committee and Our ResponseALPHA(4760)Notice of Revision to Business Forecasts for the First Half of the Fiscal Year Ending August 31, 2024TMS(4891)Presentation Material for the Fiscal Year Ended February 29,2024AEON DELIGHT(9787)[Delayed] Supplementary Information on the Financial Results for the Fiscal Year Ended February 29, 2024Segue Group(3968)[Delayed]FY2023 Financial Results BriefingAnGes(4563)Vasomune Selected to Present on AV-001 Development Status at American Thoracic Society04/16/2024Royal Holdings(8179)March 2024 Monthly Sales Report (Same-store sales)04/15/2024Saint Marc Holdings(3395)Monthly Sales Report March 2024ALPHA(4760)FY Feb-2024 Fact SheetTOHO(9602)Consolidated Financial Results for the Fiscal Year Ended February 29, 2024 (Under Japanese GAAP)HOTLAND(3196)Monthly Sales Report (March)CTI Engineering(9621)NOTICE OF THE ADJOURNMENT OF THE 61ST ANNUAL GENERAL MEETING OF SHAREHOLDERS 04/12/2024Azplanning(3490)Consolidated Financial Results for the Fiscal Year Ended February 29, 2024 (Under Japanese GAAP)HUB(3030)Non-consolidated Financial Results for the Fiscal Year Ended February 29, 2024 (Under Japanese GAAP)AnGes(4563)Notice Regarding Eiger BioPharmaceuticals, Inc.CENTRAL SECURITY PATROLS(9740)Consolidated Financial Results for the Fiscal Year Ended February 29, 2024 (Under Japanese GAAP)create restaurants holdings(3387)Notice of Reorganization within the Group(Absorption-type Merger among Consolidated Subsidiaries)Notice of Recording of Impairment LossesFinancial Results of Fiscal 2024(Supplementary Material)Summary of Business Results for the Year Ending February 29, 2024 [IFRS] (Consolidated)MELCO HOLDINGS(6676)[Delayed]Notice Concerning Change in Equity-Method Associate (Share Transfer), Recording of Extraordinary Income, and Revision of Earnings ForecastsALPHA(4760)Consolidated Financial Results for the Six Months Ended February 29, 2024 (Under Japanese GAAP)TMS(4891)Non-consolidated Financial Results for the Fiscal Year Ended February 29, 2024 [Japanese GAAP]First-corporation(1430)Summary of Financial Results for the third quarter of the fiscal year ending May 31, 2024 <Japan GAAP> (consolidated)04/11/2024LAND(8918)Consolidated Financial Results for the Fiscal Year Ended February 29, 2024 (Under Japanese GAAP)Carna Biosciences(4572)Analyst Report(Shared Research) : Poster presentation at the American Association for Cancer Research (AACR) annual meeting on the CDC7 inhibitor, monzosertibAEON DELIGHT(9787)Analyst Report(Shared Research) : Released FY02/24 results04/10/2024HUB(3030)March 2024 Monthly ReportHome Position(2999)Non-consolidated Financial Results for the Six Months Ended February 29, 2024 (Under Japanese GAAP)Carna Biosciences(4572)Carna presented a poster on monzosertib at AACR Annual MeetingAEON DELIGHT(9787)Analyst Report(Shared Research) : Decision on matters relating to acquisition of treasury shares, and establishment of Multi-stakeholder policyTOHO(9602)March 2024 Preliminary Report on Monthly Box Office Revenue (Distributed Dept./Movie Theater Chain)CTI Engineering(9621)[Delayed]61th term (2023) Financial ResultsWATTS(2735)Notice Regarding March 2024 Monthly YoY Change in Sales and Number of Shops04/09/2024AEON DELIGHT(9787)[Summary]Summary of Financial Results for the Year Ended February 29, 2024[Japan GAAP] (Consolidated)CTI Engineering(9621)Q&A on the 61st (2023) Financial Results PresentationTokyo Individualized Educational Institute(4745)Consolidated Financial Results for the Fiscal Year Ended February 29, 2024 (Under Japanese GAAP)The Monogatari Corporation(3097)Notice Regarding March 2024 Preliminary Monthly YoY Change in Sales and Number of RestaurantsVerite(9904)March 2024 Flash Report vs. LY04/08/2024Earth Corporation(4985)Analyst Report(Shared Research) : Interview following the Announcement of Financial Results for full-year FY12/23 [Report Update]ASANTE(6073)March Monthly Sales Report for FY Ending March 2024CUBE(7112)[Delayed] [FY12/24] Preliminary Monthly Sales Report of Directly Managed Stores for March 2024 New Analyst Reports 5/1 AEON DELIGHT CO.,LTD.(9787) Analyst Report(Shared Research) : Interview following the Announcement of Financial Results for FY02/24 [Report Update] 4/30 Infomart Corporation(2492) Analyst Report(Shared Research) : Released Q1 FY12/24 results 4/30 Carna Biosciences, Inc.(4572) Analyst Report(Shared Research) : Interview following the Announcement of Financial Results for full-year FY12/23 [Report Update] 4/25 EPCO Co.,Ltd.(2311) Analyst Report(Shared Research) : Monthly results for March 2024 4/8 Earth Corporation(4985) Analyst Report(Shared Research) : Interview following the Announcement of Financial Results for full-year FY12/23 [Report Update] 4/5 SBS Holdings,Inc(2384) Q&A Sessions at the Small Meeting for Institutional Investors Held on March 29 4/4 TSUBURAYA FIELDS HOLDINGS INC.(2767) Analyst Report(Shared Research) : Interview following the Announcement of Financial Results for Q3 FY03/24 [Report Update] 3/27 Fast Fitness Japan Incorporated(7092) Analyst Report(Shared Research): Acquisition of shares in Eighty 8 Health & Fitness B.V., leading to succession of the master franchise rights for Anytime Fitness in Germany. 3/27 Hakudo Co.,Ltd.(7637) Analyst Report(Shared Research) : Interview following the Announcement of Financial Results for Q3 FY03/24 [Report Update] 3/26 Ferrotec Holdings Corporation(6890) Analyst Report(Shared Research): Interview following the Announcement of Financial Results for Q3 FY03/24 [Report Update] 3/22 &Do Holdings Co.,Ltd.(3457) Shared Research Inc. research report on our company has been updated Information Information 1/19 What's new: Fast Fitness Japan (7092) 12/20 What's new: SPACE (9622) Newly Added Company Latest Video & Presentations Latest Video&Slides Company newsprovided by Timely Disclosure Network News Release Stock Code or Name: 4578 Otsuka Holdings Co.,Ltd. 04/30/2024 13:30 Consolidated Financial Results for the First Quarter of the Fiscal Year Ending December 31, 2024[IFRS] 04/26/2024 16:00 Notice Concerning Completion of Payment for Disposal of Treasury Shares as Restricted Stock Compensation 04/23/2024 08:30 [Delayed]Corporate Governance Report 04/09/2024 15:00 Otsuka and Lundbeck submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD 03/28/2024 15:00 Notice Concerning Disposal of Treasury Shares as Restricted Stock Compensation 03/27/2024 17:00 Abilify Maintena 960 mg approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia 03/15/2024 15:30 Otsuka and Sumitomo Revise License Agreement 03/15/2024 08:00 Partial Correction to the Notice of the 16th Annual Shareholders Meeting (for FY2023) 02/28/2024 08:00 Notice of the 16th Annual Shareholders Meeting (for FY2023) 02/16/2024 15:30 [Delayed]Consolidated Financial Results for the Fiscal Year Ended December 31, 2023 [IFRS] 02/16/2024 11:00 [Delayed]Notice Regarding Revision of Restricted Stock Compensation Plan 02/16/2024 11:00 [Delayed]Notice of Introduction of a Special Incentive Scheme through the Otsuka Group Employee Stock Ownership Plan 02/14/2024 13:30 Notice of Payment of Dividends 02/13/2024 08:00 Notice Regarding Revisions of Consolidated Results Forecast for FY2023 12/22/2023 15:00 Otsuka Obtains the Additional Indication of Adjunctive Treatment of Major Depressive Disorder for Rexulti in Japan 12/01/2023 08:00 Pharmavite, a U.S. subsidiary of Otsuka Pharmaceutical, acquires Bonafide Health, a provider of women's health products 11/08/2023 08:30 Otsuka Medical Devices and Recor Medical Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension 11/06/2023 13:00 Otsuka Announces Personnel Changes 11/01/2023 00:30 Environmental report 2022 10/31/2023 13:30 Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending December 31, 2023[IFRS] 10/31/2023 13:00 Otsuka Applies in Japan for the Additional Indication for Agitation Associated with Dementia due to Alzheimer's Disease for Rexulti 10/31/2023 00:30 Integrated report 2022 09/07/2023 18:00 Otsuka and Lundbeck Announce Topline Results from Two P3 Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of PTSD 09/01/2023 08:00 Notice regarding transfer of sub-subsidiary 08/23/2023 10:00 OMD and Recor Announce Positive Vote from U.S. FDA Advisory Committee Meeting on the Paradise uRDN System for the Treatment of Hypertension 07/31/2023 13:30 Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending December 31, 2023 [IFRS] 07/31/2023 08:30 Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 DIAMOND 1 and DIAMOND 2 Clinical Studies Evaluating Ulotaront in Schizophrenia 07/25/2023 15:00 Notice Regarding Revisions of Consolidated Results Forecast for the first half of FY2023 06/27/2023 08:30 Otsuka Pharmaceutical announces positive results of P3 trial in Japan showing reduced agitation in patients with AD treated with brexpiprazole 05/12/2023 13:30 Consolidated Financial Results for the First Quarter of the Fiscal Year Ending December 31, 2023 [IFRS] 05/11/2023 12:30 Otsuka and Lundbeck Announce U.S. FDA Approval of sNDA for REXULTI for the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease